Cargando…

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations

Losses of 5–10% or more of initial body weight are associated with improvements in obesity-related comorbidities. However, attaining and sustaining this level of weight loss is challenging. The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to a re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chao, Ariana M, Tronieri, Jena Shaw, Amaro, Anastassia, Wadden, Thomas A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807016/ https://www.ncbi.nlm.nih.gov/pubmed/36601368 http://dx.doi.org/10.2147/DDDT.S365416

Ejemplares similares

Alcohol Intake and Weight Loss during an Intensive Lifestyle Intervention for Adults with Overweight/Obesity and Diabetes
por: Chao, Ariana M., et al.
Publicado: (2018)

Weight Bias Internalization Is Negatively Associated With Weight-Related Quality of Life in Persons Seeking Weight Loss
por: Walsh, Olivia A., et al.
Publicado: (2018)

“Last Supper” Predicts Greater Weight Loss Early in Obesity Treatment, but Not Enough to Offset Initial Gains
por: Tronieri, Jena Shaw, et al.
Publicado: (2018)

Binge Eating and Weight Loss Outcomes in Individuals with Type 2 Diabetes: 4-Year Results from the Look AHEAD Study
por: Chao, Ariana M., et al.
Publicado: (2017)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

Wegovy (semaglutide): a new weight loss drug for chronic weight management
por: Singh, Gurdeep, et al.
Publicado: (2022)

Effects of Liraglutide on Appetite, Food Preoccupation, and Food Liking: Results of a Randomized Controlled Trial
por: Tronieri, Jena Shaw, et al.
Publicado: (2019)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

Short- and Long-Term Changes in Health-Related Quality of Life with Weight Loss: Results from a Randomized Controlled Trial
por: Pearl, Rebecca L., et al.
Publicado: (2018)

Oral Semaglutide: Dosage in Special Situations
por: Kalra, Sanjay, et al.
Publicado: (2022)

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
por: Wadden, Thomas A., et al.
Publicado: (2020)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
por: Wilding, John P. H., et al.
Publicado: (2022)

Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying
por: Fujino, Erina, et al.
Publicado: (2023)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
por: Allison, Kelly C., et al.
Publicado: (2022)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
por: Garvey, W. Timothy, et al.
Publicado: (2022)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
por: Colin, Ides M, et al.
Publicado: (2022)

Cryolipolysis: patient selection and special considerations
por: Meyer, Patricia Froes, et al.
Publicado: (2018)

Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain
por: Saulino, Michael, et al.
Publicado: (2014)

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
por: Al-Ani, Fatimah, et al.
Publicado: (2016)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
por: Chen, Xing, et al.
Publicado: (2022)

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
por: Ghusn, Wissam, et al.
Publicado: (2022)

Semaglutide single‐dose pen‐injector: Post hoc analysis of summative usability testing for weight management
por: Klonoff, David C., et al.
Publicado: (2021)

Lung transplantation in chronic obstructive pulmonary disease: patient selection and special considerations
por: Lane, C Randall, et al.
Publicado: (2015)

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations
por: Barbanti, Piero, et al.
Publicado: (2017)

Binge Eating Disorder in Patients with Type 2 Diabetes: Diagnostic and Management Challenges
por: Chevinsky, Jonathan D, et al.
Publicado: (2020)

Tympanostomy tubes: patient selection and special considerations
por: Whittemore, Kenneth R
Publicado: (2015)

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
por: Prosperini, Luca, et al.
Publicado: (2016)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtfbilahqjb9tk8i137ed6ba7p